Novo Nordisk's weight loss drug Wegovy slashes risk of serious heart events
Publishing timestamp: 2023-11-11 09:57:36
Summary
Novo Nordisk's weight-loss drug, Wegovy, has been found to significantly reduce the risk of serious cardiovascular complications in people with obesity and heart disease. The drug showed a large effect on heart attacks and demonstrated potential as a life-saving medication for chronic obesity management. The findings could expand the use of Wegovy and help Novo Nordisk maintain its lead over Eli Lilly, whose competing weight-loss drug has recently been approved. The study also found that Wegovy reduced the risk of non-fatal heart attacks and showed a reduction in overall cardiovascular events. However, there were some side effects associated with the drug, such as gastrointestinal issues. Despite limitations in the study's diversity, doctors expect the results to increase the number of people taking Wegovy.
Sentiment: POSITIVE
Tickers: NOVO.B-DK,
Keywords: science, business news, novo nordisk a/s, business, social issues, health care industry, pharmaceuticals,